Retatrutide
Triple agonist (GLP-1/GIP/Glucagon) for weight loss
Overview
Retatrutide is a novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. It represents the next generation of weight loss peptides with unprecedented efficacy in clinical trials.
Mechanism of Action
Activates three receptors: GLP-1 (appetite suppression, insulin) + GIP (incretin enhancement) + Glucagon (thermogenesis, fat oxidation) → synergistic metabolic effects.
Benefits
- Up to 24% body weight loss in trials
- Triple receptor activation
- Enhanced thermogenesis
- Improved metabolic markers
- Once-weekly dosing
Dosing Protocol
Half-Life
~6 days
Duration of pharmacological activity after administration.
Side Effects
- Nausea
- Diarrhea
- Vomiting
- Decreased appetite
- Constipation
Stacking Recommendations
Storage & Reconstitution
Refrigerate at 2–8°C. Do not freeze.
Research Notes
Phase 2 results showed 24.2% weight loss at 48 weeks (highest dose). Eli Lilly development. Phase 3 trials ongoing. Could become the most effective single-agent weight loss therapy.
Medical Disclaimer
This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment recommendations. Peptide therapy should only be initiated under the supervision of a qualified healthcare provider. Individual results may vary. Always consult with your physician before starting any new therapy. Regulatory status varies by jurisdiction.